Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 144

1.

Aspirin therapy is still underutilized among patients with type 2 diabetes.

Leitão CB, Krahe AL, Nabinger GB, Picon PX, Pecis M, Zaslavsky LM, Gross JL, Canani LH.

Arq Bras Endocrinol Metabol. 2006 Dec;50(6):1014-9.

2.

Use of antiplatelet therapy in a diabetic outpatient service of a large urban public hospital.

Bruno A, Grassi G, Dani F, Degiovanni M, Maghenzani G, Pagano G.

Nutr Metab Cardiovasc Dis. 2005 Feb;15(1):42-6.

PMID:
15871850
3.

The benefit of aspirin therapy in type 2 diabetes: what is the evidence?

Sirois C, Poirier P, Moisan J, Grégoire JP.

Int J Cardiol. 2008 Sep 26;129(2):172-9. doi: 10.1016/j.ijcard.2008.01.030. Epub 2008 May 20. Review.

PMID:
18495263
4.

[Aspirin for the primary prevention of cardiovascular diseases in diabetic patients. A review of currently available tests].

Maciá Bobes C, Ronzón Fernández A, Fernández García E.

Rev Esp Salud Publica. 2006 Nov-Dec;80(6):613-20. Review. Spanish.

6.

Decisional attributes of patients with diabetes: the aspirin choice.

Montori VM, Bryant SC, O'Connor AM, Jorgensen NW, Walsh EE, Smith SA.

Diabetes Care. 2003 Oct;26(10):2804-9.

PMID:
14514583
7.

Changing aspirin use in patients with Type 2 diabetes in the UKPDS.

Cull CA, Neil HA, Holman RR.

Diabet Med. 2004 Dec;21(12):1368-71.

PMID:
15569143
8.

Aspirin for primary prevention in patients with diabetes mellitus.

Nguyen KX, Marinac JS, Sun C.

Fam Med. 2005 Feb;37(2):112-7.

9.

[Use of aspirin in diabetic patients].

Türkoğlu S, Abaci A.

Anadolu Kardiyol Derg. 2007 Dec;7 Suppl 2:5-8. Review. Turkish.

11.
12.

The combined use of aspirin, a statin, and blood pressure-lowering agents (polypill components) in clinical practice in patients with vascular diseases or type 2 diabetes mellitus.

Lafeber M, Grobbee DE, Spiering W, van der Graaf Y, Bots ML, Visseren FL; SMART Study Group.

Eur J Prev Cardiol. 2013 Oct;20(5):771-8. doi: 10.1177/2047487312449587. Epub 2012 May 30.

PMID:
22649123
13.

AHA/ADA vs. ESC/EASD recommendations on aspirin as a primary prevention strategy in people with diabetes: how the same data generate divergent conclusions.

Nicolucci A, De Berardis G, Sacco M, Tognoni G.

Eur Heart J. 2007 Aug;28(16):1925-7. Epub 2007 Jun 29.

PMID:
17604291
14.

[Should we treat all diabetic patients with aspirin in primary prevention?].

Righetti A, De Moerloose P, Philippe J.

Rev Med Suisse. 2005 Jun 1;1(22):1500-4. Review. French.

PMID:
16025889
15.

Aspirin in the treatment of type 2 diabetes.

Kajubi SK.

Arch Intern Med. 2000 Feb 14;160(3):394. No abstract available.

PMID:
10668844
16.

Aspirin for primary prevention of cardiovascular events in people with diabetes: a position statement of the American Diabetes Association, a scientific statement of the American Heart Association, and an expert consensus document of the American College of Cardiology Foundation.

Pignone M, Alberts MJ, Colwell JA, Cushman M, Inzucchi SE, Mukherjee D, Rosenson RS, Williams CD, Wilson PW, Kirkman MS.

Circulation. 2010 Jun 22;121(24):2694-701. doi: 10.1161/CIR.0b013e3181e3b133. Epub 2010 May 27. No abstract available.

17.

Improving aspirin prophylaxis in a primary care diabetic population.

Faragon JJ, Waite NM, Hobson EH, Seoldo N, VanAmburgh JA, Migden H.

Pharmacotherapy. 2003 Jan;23(1):73-9.

PMID:
12523462
18.

[Aspirin therapy for cardiovascular prevention in the diabetic patient: what have we learned from the evidence?].

Legrand DA, Scheen AJ.

Rev Med Suisse. 2006 Aug 23;2(76):1904-8. Review. French.

19.

Evaluation of aspirin use in patients with diabetes receiving care in community health.

Fosmire Rundgren EW, Anderson SL, Marrs JC.

Ann Pharmacother. 2015 Feb;49(2):170-7. doi: 10.1177/1060028014554444. Epub 2014 Oct 6.

PMID:
25288823
20.

[Acetylsalicylic acid and diabetes mellitus].

Paiva S.

Acta Med Port. 2002 May-Jun;15(3):199-202. Review. Portuguese.

Supplemental Content

Support Center